

Form PTO-1449 (modified)

Atty. Docket No.

UTSD:729USD2

Serial No.

10/759,625

List of Patents and Publications for Applicant's

Applicant

Eric Olson

Norbert Frey

INFORMATION DISCLOSURE STATEMENT

Filing Date:

January 16, 2004

Group:

Unknown

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 96 12806 A	5-2-96	PCT			
	B2	WO 99 19473 A	4-22-99	PCT			
	B3	WO 01 53312 A	7-26-01	PCT			
	B4	WO 01 92567 A	12-6-01	PCT			
	B5	WO 02 04491 A	1-17-02	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Ahmad et al., "Homo sapiens muscle-specific protein (C4 or C5)," Abstract, DATABASE EMBL 'Online!', Database Accession No. AF249873, 2000.
	C2	Ahmad et al., "Identification and characterization of a novel gene (C4orf5) located on human chromosome 4q with specific expression in cardiac and skeletal muscle," <i>Genomics</i> , 70:347-353, 2000.
	C3	Ding et al., "Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin," <i>Circ Res.</i> , 84(6):729-734, 1999.
	C4	Faulkner et al., "FATZ: a filamin, actinin, and telethonin binding protein of the Z-disk of skeletal muscle," <i>Journ. Bio. Chem.</i> , 275:41234-41242, 2000.
	C5	Frey et al., "Calsarcins, a novel family of sarcomeric calcineurin-binding proteins," <i>Proc. Natl. Acad. Sci. USA</i> , 97:14632-14637, 2000.
	C6	Fuentes et al., "DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways," <i>Human Mol. Gen., Oxford University Press, U.K.</i> , 9:1681-1690, 2000.

25403089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSD:729USD2	Serial No. 10/759,625
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Eric Olson Norbert Frey	
		Filing Date: January 16, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C7	GenBank accession number AA036142
	C8	GenBank accession number AA176945
	C9	GenBank accession number AA197193
	C10	GenBank accession number W29466
	C11	GenBank accession number AC008453.3
	C12	GenBank accession number AW000988
	C13	GenBank accession number AW742494
	C14	GenBank accession number AW964108
	C15	Alignment of SEQ. ID. No. 2 with SEQ. ID No. 286 of USSN 10/098,841, PG PUB No. 210020197679A1.
	C16	Hill <i>et al.</i> , "Cardiac hypertrophy is not a required compensatory response to short-term pressure overload," <i>Circulation</i> , 101(24):2863-2869, 2000.
	C17	Ievolella, "Homo sapiens mRNA for FATZ related protein 2 (ORF1)," Abstract, DATABASE EMBL 'Online', EBI Database Acession No. AJ252149, 2000.
	C18	Lim <i>et al.</i> , "Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy," <i>Circulation</i> , 101(20):2431-2437, 2000.
	C19	Lim <i>et al.</i> , "Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition," <i>J Mol Cell Cardiol</i> , 32(4):697-709, 2000.
	C20	Marban <i>et al.</i> , "Intracellular free calcium concentration measured with <sup>19</sup> F NMR spectroscopy in intact ferret hearts," <i>Proc Natl Acad Sci U S A</i> , 84:6005-6009, 1987.
	C21	Molkentin <i>et al.</i> , "A calcineurin-dependent transcriptional pathway for cardiac hypertrophy," <i>Cell</i> , 93:215-228, 1998.
	C22	Rothermel <i>et al.</i> , "A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling," <i>J. Bio. Chem.</i> , 275:8719-8725, 2000.
	C23	Seidman and Seidman, "Molecular genetic studies of familial hypertrophic cardiomyopathy," <i>Basic Res Cardiol.</i> ;93 Suppl 3:13-16, 1998.

25403089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSD:729USD2	Serial No. 10/759,625
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Eric Olson Norbert Frey	
		Filing Date: January 16, 2004	Group: Unknown
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C24	Shimoyama <i>et al.</i> , "Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy," <i>Circulation</i> , 100(24):2449-2454, 1999.
	C25	Sussman <i>et al.</i> , "Prevention of cardiac hypertrophy in mice by calcineurin inhibition," <i>Science</i> , 281:1690-1693, 1998.
	C26	Zhang <i>et al.</i> , "Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats," <i>Circ Res.</i> , 84(6):722-728, 1999.

25403089.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.